LONDON, November 11 /PRNewswire/ -- Extensive research conducted by the Imperial College of London, Ghent University Hospital and University of Sheffield on the Simbionix PROcedure Rehearsal Studio(TM), was awarded a Magna Cum Laude EPOS Award at the CIRSE 2009 congress in Lisbon, Portugal.
The PROcedure Rehearsal Studio(TM), introduced by Simbionix last year, is the world's first patient specific system to enable clinicians to create practice scenarios based on their patient's unique anatomy as reconstructed from CTA or MRA data.
Preliminary data from ongoing research by the European Virtual Reality Endovascular Research Team (EVEResT) suggests that patient-specific rehearsal may enhance the performance of interventionalists in subsequent endovascular procedures. The preliminary data also suggested that after rehearsal, endovascular surgery is carried out more rapidly with less use of contrast and fluoroscopy and to a higher qualitative standard, compared to those interventions preceded by a generic warm-up case, or no warm-up at all.
Professor Nick Cheshire, Professor of Vascular Surgery at Imperial College remarks: "We are pleased to report on the strong correlation between the virtual and real operation with regards to the angiography images, endovascular access and material used during the intervention. The Rehearsal Studio was able to adequately predict the optimal material for the specific case at hand. Further research into the PROcedure Rehearsal Studio(TM) is expected to determine if this technology can indeed help to improve the technical skills of the interventionalist and tailor these skills to the challenges of a specific patient. The preliminary results already demonstrate shorter procedure time with less use of contrast; the end goal of the application of this technique will of course be to enhance patient safety and outcome."
Mr. Ran Bronstein, President and COO at Simbionix adds: "We are very pleased with the results of the research work conducted on our newest system. The PROcedure Rehearsal Studio(TM) is an innovative product that utilizes a unique technology which was developed following intensive R&D efforts. Based on initial reactions, I believe it will change the way physicians practice and perform today."
About Imperial College Londonthe EVEResT Research Group
The EVEResT research group, led by Professor N. Cheshire, is a multicenter collaboration between the Imperial College London in the U.K., the University Hospital Ghent in Belgium (Prof. F. Vermassen) and the Sheffield Vascular Institute in the U.K.(Prof. P. Gaines).
The research group is multidisciplinary in nature, consisting of vascular surgeons, radiologists and cardiologists. Its main goal is to provide a platform for research into medical simulation and to aid the process of validation and implementation of endovascular simulation as both a training, credentialing and procedure rehearsal tool.
About Simbionix USA Corporation
Simbionix is the leader in the development and delivery of innovative and effective virtual reality simulation products and solutions for clinical education and training of medical professionals. The products are designed to accelerate best-practice medical training, advance clinical performance, and improve patient safety.
The Simbionix product line includes the ANGIO Mentor(TM) line for endovascular procedures, LAP Mentor(TM) line for laparoscopic surgical procedures, GI Mentor(TM) for upper and lower gastrointestinal procedures and the URO Mentor(TM) for urological procedures. In addition, Simbionix distributes the HystSim(TM) for hysteroscopic procedures. Each simulation platform is a leading simulator in the relevant clinical area.
Simbionix simulation products have been validated in several scientific studies and the company cooperates closely with both industry and leading medical institutions to develop the most advanced simulators for the training and assessment of medical professionals.
Galia Zilbershtein-Salant Exhibition Manager Simbionix Tel: +972-8-9211177 firstname.lastname@example.org
SOURCE Simbionix Ltd.
|SOURCE Simbionix Ltd.|
Copyright©2009 PR Newswire.
All rights reserved